Wouter W. Mellema

462 citations

17 papers · 387 indexed · h-index 8

Oncology
- Lung Cancer Research Studies 5
- Colorectal Cancer Treatments and Studies 3
- Cytokine Signaling Pathways and Interactions 2
- Cancer-related Molecular Pathways 2
Internal Medicine
- Venous Thromboembolism Diagnosis and Management 2
Pulmonary and Respiratory Medicine top 10%
- Lung Cancer Treatments and Mutations 11
Cancer Research
Molecular Biology
- PI3K/AKT/mTOR signaling in cancer 5
Hepatology
- Hepatocellular Carcinoma Treatment and Prognosis 2

Co-authors: Egbert F. Smit Anne‐Marie C. Dingemans Daniëlle A.M. Heideman Sjaak A. Burgers Erik Thunnissen Lizza Hendriks Harry J.M. Groen Cordula Pitz
Cited by: Oncology Internal Medicine Pulmonary and Respiratory Medicine
Journals: Journal of Clinical Oncology (2 papers)Cancer Research (1 paper)Clinical Cancer Research (2 papers)
Partner nations: Netherlands United States

In The Last Decade

Wouter W. Mellema

17 papers receiving 383 citations

Peers

Countries citing papers authored by Wouter W. Mellema

Since Specialization

Citations

This map shows the geographic impact of Wouter W. Mellema's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Wouter W. Mellema with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Wouter W. Mellema more than expected).

Fields of papers citing papers by Wouter W. Mellema

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Wouter W. Mellema. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Wouter W. Mellema. The network helps show where Wouter W. Mellema may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Wouter W. Mellema, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Wouter W. Mellema Line = papers co-authored together Wouter W. Mellema links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

17 of 17 papers shown

#	Work
1	LBA50 A randomized phase III study comparing cisplatin-pemetrexed (cis-pem) with carboplatin (C)-paclitaxel (P)-bevacizumab (B) in chemotherapy naïve patients (pts) with advanced KRAS mutated non-small cell lung cancer (NSCLC): NVALT22 Annals of Oncology ·Anne‐Marie C. Dingemans,Scott Ernst,Wouter W. Mellema,Sjaak A. Burgers,J. Staal-van den Brekel,Lizza Hendriks,T. Jeroen N. Hiltermann,Nico van Walree,K.W. Maas,M. Youssef-El-Soud,Bonne Biesma,Vera E. van der Noord,Egbert F. Smit,J.A. De Langen	2021	4
2	Comparison of clinical outcome after first-line platinum-based chemotherapy in different types of KRAS mutated advanced non-small-cell lung cancer Lung Cancer ·Wouter W. Mellema,Lucie Masen-Poos,Egbert F. Smit,Lizza Hendriks,Joachim G.J.V. Aerts,A. Termeer,Martijn Goosens,Hans J.M. Smit,Michel M. van den Heuvel,Anthonie J. van der Wekken,Gerarda J.M. Herder,Frans H. Krouwels,Jos A. Stigt,Ben E.E.M. van den Borne,T. Haitjema,A.J. Staal-van den Brekel,Robbert C. van Heemst,E.M. Pouw,Anne‐Marie C. Dingemans	2015	32
3	EGFR mutated non-small cell lung cancer patients: More prone to development of bone and brain metastases? Lung Cancer ·Lizza Hendriks,Egbert F. Smit,Bettine A.H. Vosse,Wouter W. Mellema,Daniëlle A.M. Heideman,Gerben Bootsma,Marcel Westenend,Cordula Pitz,Geeuwke J. de Vries,Ruud Houben,Katrien Grünberg,Mátyás Béndek,E-J M Speel,Anne‐Marie C. Dingemans	2014	95
4	Retrospective analysis of type of KRAS mutation (mut) and response to first-line platinum-based chemotherapy (PC) in non-small cell lung cancer (NSCLC) patients (pts). Journal of Clinical Oncology ·Wouter W. Mellema,Lucie Masen-Poos,Lizza Hendriks,Anthonie J. van der Wekken,Joachim G.J.V. Aerts,Judith Herder,Jos A. Stigt,Ben van den Borne,Michel M. van den Heuvel,E.M. Pouw,Anne‐Marie C. Dingemans,Egbert F. Smit	2014	1
5	Sorafenib synergizes with metformin in NSCLC through AMPK pathway activation International Journal of Cancer ·Floris H. Groenendijk,Wouter W. Mellema,Eline van der Burg,Eva Schut,Michael Hauptmann,Hugo M. Horlings,Stefan M. Willems,Michel M. van den Heuvel,Jos Jonkers,Egbert F. Smit,René Bernards	2014	61
6	Tumor flare after start of RAF inhibition in KRAS mutated NSCLC: A case report Lung Cancer ·Wouter W. Mellema,Sjaak A. Burgers,Egbert F. Smit	2014	22
7	Retrospective evaluation of thromboembolic events in patients with non-small cell lung cancer treated with platinum-based chemotherapy Lung Cancer ·Wouter W. Mellema,Dorien van der Hoek,Pieter E. Postmus,Egbert F. Smit	2014	25
8	Sorafenib and metformin in pretreated patients with stage IV non-small cell lung cancer with a KRAS mutation: A multicenter single arm phase II study. Journal of Clinical Oncology ·Wouter W. Mellema,Sjaak A. Burgers,Harry J.M. Groen,Anne‐Marie C. Dingemans,Erik Thunnissen,Daniëlle A.M. Heideman,Egbert F. Smit	2014	4
9	Analysis of AKT and ERK1/2 protein kinases in extracellular vesicles isolated from blood of patients with cancer Journal of Extracellular Vesicles ·Johannes C. van der Mijn,Nik Sol,Wouter W. Mellema,Connie R. Jiménez,Sander R. Piersma,Henk Dekker,Lisette M. Schütte,Egbert F. Smit,Henk J. Broxterman,Johan Skog,Bakhos A. Tannous,Thomas Würdinger,Henk M.W. Verheul	2014	32
10	KRAS Mutations in Advanced Nonsquamous Non–Small-Cell Lung Cancer Patients Treated with First-Line Platinum-Based Chemotherapy Have No Predictive Value Journal of Thoracic Oncology ·Wouter W. Mellema,Anne‐Marie C. Dingemans,Erik Thunnissen,Peter J.F. Snijders,Jules L. Derks,Daniëlle A.M. Heideman,Robert‐Jan van Suylen,Egbert F. Smit	2013	36
11	Sorafenib in Non-Small Cell Lung Cancer—Results of Clinical Trials Wouter W. Mellema,Egbert F. Smit,Anne‐Marie C. Dingemans	2013	2
12	A PHASE II STUDY OF SORAFENIB AND METFORMIN IN PATIENTS WITH STAGE IV NON-SMALL CELL LUNG CANCER (NSCLC) WITH A KRAS MUTATION Data Archiving and Networked Services (DANS) ·Wouter W. Mellema,Sjaak Burgers,Harry J.M. Groen,Anne‐Marie C. Dingemans,Erik Thunnissen,Daniëlle A.M. Heideman,Jeroen de Jong,Wim Timens,Ernst‐Jan M. Speel,Egbert F. Smit	2013	1
13	Abstract 3635: A retrospective evaluation of metformin usage in patients with small cell lung cancer (SCLC). Cancer Research ·Wouter W. Mellema,Mieke J. Aarts,Myrthe P. P. van Herk‐Sukel,Egbert F. Smit	2013	1
14	A Phase II Study of Sorafenib in Patients with Platinum-Pretreated, Advanced (Stage IIIb or IV) Non–Small Cell Lung Cancer with a KRAS Mutation Clinical Cancer Research ·Anne‐Marie C. Dingemans,Wouter W. Mellema,Harry J.M. Groen,Atie van Wijk,Sjaak A. Burgers,Peter W.A. Kunst,Erik Thunnissen,Daniëlle A.M. Heideman,Egbert F. Smit	2012	63
15	Abstract PR5: A phase II study of sorafenib in patients with stage IV non-small cell lung cancer (NSCLC) with a K-Ras mutation Clinical Cancer Research ·Wouter W. Mellema,Anne‐Marie C. Dingemans,Harry J.M. Groen,Atie van Wijk,Sjaak A. Burgers,Peter W.A. Kunst,Erik Thunnissen,Daniëlle A.M. Heideman,Egbert F. Smit	2012	1
16	Low molecular weight heparins in the treatment of lung cancer Expert Opinion on Investigational Drugs ·Wouter W. Mellema,Egbert F. Smit,Anne‐Marie C. Dingemans	2011	5
17	A Phase II Study of Sorafenlb In Patients with Locally Advanced And/or Metastatic (stage 1MB or IV) Non-small Cell Lung Cancer (NSCLC) with a K-Ras Mutation European Journal of Cancer ·A.M. Dinqemans,Wouter W. Mellema,Harry J.M. Groen,A. van Wijk,Sjaak A. Burgers,Peter W.A. Kunst,Erik Thunnissen,Daniëlle A.M. Heideman,Egbert F. Smit	2011	2

About Wouter W. Mellema

Wouter W. Mellema is a scholar working on Internal Medicine, Oncology and Pulmonary and Respiratory Medicine, having authored 17 papers that have together received 387 indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (11 papers), Lung Cancer Research Studies (5 papers), PI3K/AKT/mTOR signaling in cancer (5 papers), Colorectal Cancer Treatments and Studies (3 papers), Venous Thromboembolism Diagnosis and Management (2 papers), Cytokine Signaling Pathways and Interactions (2 papers), Hepatocellular Carcinoma Treatment and Prognosis (2 papers) and Cancer-related Molecular Pathways (2 papers). The work is most often cited by research in Oncology (232 citations), Internal Medicine (24 citations) and Pulmonary and Respiratory Medicine (207 citations). Wouter W. Mellema has collaborated with scholars based in Netherlands and United States. Frequent co-authors include Egbert F. Smit, Anne‐Marie C. Dingemans, Daniëlle A.M. Heideman, Sjaak A. Burgers, Erik Thunnissen, Lizza Hendriks, Harry J.M. Groen, Cordula Pitz, Bettine A.H. Vosse and Peter W.A. Kunst. Their work appears in journals such as Journal of Clinical Oncology, Cancer Research and Clinical Cancer Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact